Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06656390
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-20
Brief Title:
A Study to Evaluate the Safety Tolerability Pharmacokinetics PK and Antitumor Activity of ALK201 in Participants with Advanced Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A First-in-Human Open-Label Multi-Center Phase III Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Adult Participants with Advanced Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first-in-human FIH open-label multicenter dose escalation and expansion study of ALK201 The purpose of this study is to evaluate the safety tolerability pharmacokinetics PK and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors The study will also identify recommended doses for subsequent clinical studies of ALK201
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None